Design of novel anti-idiotype vaccines adjuvanted with RNA-based nanoparticles: entry into nanotechnology based personalized cancer immunotherapy.

Acronym
Nanovaxid

Project partners
- Karl-Josef Kallen | CureVac | Tübingen | GERMANY
- Jan Walewski | Department of Lymphoid Malignancies | Maria Sklodowska-Curie Memorial Institute and Oncology Centre | Warszawa | POLAND

Abstract
Follicular lymphoma is an indolent and yet incurable malignancy. Idiotype vaccination is an experimental strategy designed to prevent disease relapse after mild chemotherapy by instructing the patient’s own immune system to recognize and eliminate residual tumor cells. Currently, idiotypic vaccination succeeds in no more than half of the patients. In this study, we plan to replace the adjuvant molecules of the old formulation with a single, powerful, RN-nano-adjuvant, which will be evaluated both at the preclinical and clinical level.